ArticleDrug delivery and translational research2026
Controlled co-delivery of anti-inflammatory drugs from bilayer polymer films coating a meniscus implant.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preparation and Characterization of PCL/PEO-PVP ECM-Mimicking Coaxial Electrospun Membranes Loaded with Ciprofloxacin and Curcumin for Sequential Dual-Drug Release.Biomimetics (Basel, Switzerland) · 2026Article
- [Advances in immunomodulatory strategies for meniscal regeneration].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Porogen-Mediated Barrier Control in Multilayered Drug-Eluting Antibacterial Films: Comparative Evaluation of PEG, PVP, and PEOx.Pharmaceutics · 2026Article
- Targeting the mitochondrial metabolite-dynamics-MDVs-MitoEVs axis: a new frontier in osteoarthritis management.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knee osteoarthritis (OA), a degenerative joint disease, is increasingly prevalent worldwide and often results from a meniscal deterioration that leads to meniscus removal. Replacing the damaged meniscus with a non-biodegradable prosthesis offers an innovative solution to prevent OA progression, particularly in older patients. However, the long-term use of anti-inflammatory drugs for pain relief and prosthesis integration can cause severe off-target side effects. The objective of this work was to design and develop drug-loaded bilayer polymer films to be used as coatings for a meniscus polycarbonate urethane (PCU). The developed bilayer polymer films enabled a sustained release of two anti-inflammatory drugs - dexamethasone (DEX) and celecoxib (CLX) - with distinct release kinetics (1-4 weeks for DEX and 6-9 months for CLX). This release profile was defined to modulate post-surgical and chronic inflammation within the knee joint, respectively. Two bilayer prototypes showed consistent biodegradation, drug release, drug loading, and reproducibility. Furthermore, the systems were sterile, biocompatible, and maintained the anti-inflammatory efficacy of the released drugs, effectively reducing pro-inflammatory cytokine secretion from human primary macrophages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.